Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
2014 · New England Journal of Medicine · 3,004 citations
https://doi.org/10.1056/nejmoa1405095
P
Peter Iversen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
378
Papers
13.9K
Citations
54
h-index
152
i10-index
Peter Iversen is an academic researcher from Aarhus University. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Prostate Cancer Diagnosis and Treatment & Cancer, Lipids, and Metabolism. The author has an h-index of 54, co-authored 322 publications.
ORCID: 0000-0003-2455-5142Papers by this author
worksAssociation analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
2018 · Nature Genetics · 994 citations
https://doi.org/10.1038/s41588-018-0142-8
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
2021 · Nature Genetics · 484 citations
https://doi.org/10.1038/s41588-020-00748-0
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
2018 · BMJ · 216 citations
https://doi.org/10.1136/bmj.j5757
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
2018 · Nature Communications · 113 citations
https://doi.org/10.1038/s41467-018-04109-8
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results
2015 · European Urology · 45 citations
https://doi.org/10.1016/j.eururo.2015.01.027
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat